Compare NAK & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAK | ARDX |
|---|---|---|
| Founded | 1983 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2002 | 2014 |
| Metric | NAK | ARDX |
|---|---|---|
| Price | $1.33 | $6.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $2.50 | ★ $14.67 |
| AVG Volume (30 Days) | ★ 10.9M | 3.8M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | N/A | $35.64 |
| Revenue Next Year | N/A | $34.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.64 | $3.50 |
| 52 Week High | $2.98 | $8.40 |
| Indicator | NAK | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 36.66 | 45.71 |
| Support Level | $0.81 | $5.49 |
| Resistance Level | $1.59 | $6.69 |
| Average True Range (ATR) | 0.13 | 0.36 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 21.12 | 56.75 |
Northern Dynasty Minerals Ltd is a mineral exploration company. It has a single operating segment of acquisition, exploration, and development of mineral properties. Its core asset is the Pebble Project located in Alaska, USA. The Pebble project is seeking to develop a deposit of copper, gold, molybdenum, and silver into a modern mining operation.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.